title: Novel approaches and challenges to treatment of central nervous system viral infections.
abstract: Existing and emerging viral central nervous system (CNS) infections are major sources of human morbidity and mortality. Treatments of proven efficacy are currently limited predominantly to herpesviruses and human immunodeficiency virus (HIV). Development of new therapies has been hampered by the lack of appropriate animal model systems for some important viruses and by the difficulty in conducting human clinical trials for diseases that may be rare, or in the case of arboviral infections, often have variable seasonal and geographic incidence. Nonetheless, many novel approaches to antiviral therapy are available, including candidate thiazolide and pyrazinecarboxamide derivatives with potential broad-spectrum antiviral efficacy. New herpesvirus drugs include viral helicase-primase and terminase inhibitors. The use of antisense oligonucleotides and other strategies to interfere with viral RNA translation has shown efficacy in experimental models of CNS viral disease. Identifying specific molecular targets within viral replication cycles has led to many existing antiviral agents and will undoubtedly continue to be the basis of future drug design. A promising new area of research involves therapies based on enhanced understanding of host antiviral immune responses. Toll-like receptor agonists and drugs that inhibit specific cytokines as well as interferon preparations have all shown potential therapeutic efficacy. Passive transfer of virus-specific cytotoxic T lymphocytes has been used in humans and may provide an effective therapy for some herpesvirus infections and potentially for progressive multifocal leukoencephalopathy. Humanized monoclonal antibodies directed against specific viral proteins have been developed and in several cases evaluated in humans in settings including West Nile virus and HIV infection and in pre-exposure prophylaxis for rabies.
authors.affiliation: Section of Infections of the Nervous Systems, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD.
authors.forename: Avindra
authors.initials: A
authors.lastname: Nath
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Tyler
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D020805:Central Nervous System Viral Diseases / Q000188:drug therapy*; D015195:Drug Design; D015658:HIV Infections / Q000188:drug therapy*; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans
chemical_list: D000998:Antiviral Agents
references.citation: Med Res Rev. 2013 Nov;33(6):1249-77
references.pmid: 23495004
references.citation: Nat Rev Neurol. 2010 Dec;6(12):667-79
references.pmid: 21131916
references.citation: Arthritis Rheum. 2012 Sep;64(9):3043-51
references.pmid: 22422012
references.citation: Med Microbiol Immunol. 2010 Aug;199(3):261-71
references.pmid: 20390298
references.citation: AIDS. 2011 Mar 13;25(5):577-80
references.pmid: 21160414
references.citation: BMC Infect Dis. 2012 Jan 26;12:23
references.pmid: 22276993
references.citation: Clin Dev Immunol. 2011;2011:370872
references.pmid: 21461372
references.citation: Antiviral Res. 2009 Jan;81(1):6-15
references.pmid: 18796313
references.citation: Lancet Infect Dis. 2012 May;12(5):397-407
references.pmid: 22541629
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11311-6
references.pmid: 12186974
references.citation: Nature. 2011 Nov 30;481(7379):81-4
references.pmid: 22139420
references.citation: J Infect Dis. 2005 Nov 15;192(10):1741-8
references.pmid: 16235172
references.citation: J Neurovirol. 2011 Feb;17(1):3-16
references.pmid: 21174240
references.citation: Blood. 2011 Mar 10;117(10):2791-9
references.pmid: 21148083
references.citation: Antimicrob Agents Chemother. 2011 Oct;55(10):4631-8
references.pmid: 21825302
references.citation: Arch Neurol. 2009 Aug;66(8):939-48
references.pmid: 19667214
references.citation: Antimicrob Agents Chemother. 2011 Apr;55(4):1349-57
references.pmid: 21245446
references.citation: Lancet. 2006 Jul 8;368(9530):124-9
references.pmid: 16829296
references.citation: Antimicrob Agents Chemother. 2009 Feb;53(2):450-7
references.pmid: 19015347
references.citation: Antiviral Res. 2012 Sep;95(3):242-4
references.pmid: 22728256
references.citation: J Antimicrob Chemother. 2010 May;65(5):953-61
references.pmid: 20299495
references.citation: Virology. 2012 May 10;426(2):100-5
references.pmid: 22341308
references.citation: PLoS One. 2012;7(10):e47506
references.pmid: 23082173
references.citation: BMC Neurosci. 2013 Feb 07;14:19
references.pmid: 23391218
references.citation: Antiviral Res. 2012 Dec;96(3):414-21
references.pmid: 23043942
references.citation: Dis Model Mech. 2012 May;5(3):313-22
references.pmid: 22563057
references.citation: Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42
references.pmid: 20660677
references.citation: J Neurovirol. 2001 Aug;7(4):353-7
references.pmid: 11517416
references.citation: Transfusion. 2011 Mar;51(3):591-9
references.pmid: 21133926
references.citation: J Virol. 2010 Dec;84(23):12125-38
references.pmid: 20881045
references.citation: Antiviral Res. 1999 Nov;44(1):75-8
references.pmid: 10588335
references.citation: J Virol. 2004 Aug;78(15):8312-21
references.pmid: 15254203
references.citation: Science. 2006 Oct 13;314(5797):308-12
references.pmid: 16973841
references.citation: PLoS One. 2011;6(10):e26304
references.pmid: 22028851
references.citation: Vaccine. 2008 Nov 5;26(47):5922-7
references.pmid: 18804136
references.citation: Immunity. 2009 Feb 20;30(2):242-53
references.pmid: 19200759
references.citation: Virus Res. 2012 Nov;169(2):388-410
references.pmid: 22728445
references.citation: Curr Opin Neurol. 2011 Jun;24(3):284-90
references.pmid: 21499099
references.citation: PLoS One. 2011;6(9):e24745
references.pmid: 21935451
references.citation: Viruses. 2012 Dec 17;4(12):3812-30
references.pmid: 23247502
references.citation: Eur J Immunol. 2007 Jul;37(7):1845-54
references.pmid: 17559174
references.citation: J Virol. 2008 Jul;82(14):7009-21
references.pmid: 18480437
references.citation: J Infect Dis. 2010 Jan 15;201(2):178-85
references.pmid: 20025530
references.citation: Blood. 2010 Nov 18;116(20):4360-7
references.pmid: 20625005
references.citation: PLoS One. 2010 May 07;5(5):e10537
references.pmid: 20479874
references.citation: Antimicrob Agents Chemother. 2012 Mar;56(3):1390-402
references.pmid: 22203590
references.citation: Arch Neurol. 2009 Sep;66(9):1065-74
references.pmid: 19752295
references.citation: N Engl J Med. 2011 Oct 6;365(14):1284-92
references.pmid: 21991950
references.citation: J Infect Dis. 2011 Dec 15;204(12):1936-45
references.pmid: 22021620
references.citation: N Engl J Med. 1986 Jan 16;314(3):144-9
references.pmid: 3001520
references.citation: J Infect Dis. 2004 Sep 15;190(6):1084-7
references.pmid: 15319857
references.citation: Curr HIV Res. 2003 Oct;1(4):373-83
references.pmid: 15049424
references.citation: BMC Infect Dis. 2011 Oct 21;11:281
references.pmid: 22018204
references.citation: Semin Neurol. 2011 Jul;31(3):245-53
references.pmid: 21964843
references.citation: Lancet. 2003 Mar 8;361(9360):821-6
references.pmid: 12642049
references.citation: Antimicrob Agents Chemother. 2010 Jun;54(6):2431-6
references.pmid: 20350945
references.citation: Virology. 2013 Jan 20;435(2):320-8
references.pmid: 23084424
references.citation: PLoS Pathog. 2009 Feb;5(2):e1000321
references.pmid: 19247438
references.citation: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
references.pmid: 11259830
references.citation: J Exp Med. 2011 Sep 26;208(10):2083-98
references.pmid: 21911422
references.citation: J Virol. 2005 Nov;79(21):13350-61
references.pmid: 16227257
references.citation: J Neuropathol Exp Neurol. 2007 Jun;66(6):533-44
references.pmid: 17549013
references.citation: J Virol. 2012 Feb;86(4):2273-81
references.pmid: 22171256
references.citation: J Infect Dis. 2008 Mar 1;197(5):721-7
references.pmid: 18266604
references.citation: J Exp Med. 2012 Aug 27;209(9):1567-82
references.pmid: 22851595
references.citation: Blood. 2013 May 23;121(21):4321-9
references.pmid: 23589672
references.citation: Aliment Pharmacol Ther. 2006 Sep 1;24(5):887-94
references.pmid: 16918894
references.citation: Clin Infect Dis. 2011 Jan 1;52(1):49-57
references.pmid: 21148519
references.citation: Scand J Infect Dis. 2005;37(11-12):944-6
references.pmid: 16308241
references.citation: J Virol. 2013 Mar;87(6):3361-75
references.pmid: 23302871
references.citation: JAMA. 2013 Mar 6;309(9):887-95
references.pmid: 23462785
references.citation: J Virol. 1990 Jun;64(6):3087-90
references.pmid: 2335829
references.citation: Nat Rev Microbiol. 2013 Jul;11(7):482-96
references.pmid: 23748342
references.citation: Arthritis Rheum. 2010 Nov;62(11):3191-5
references.pmid: 20722036
references.citation: Am J Pathol. 2010 Nov;177(5):2433-45
references.pmid: 20864677
references.citation: JAMA. 2009 Feb 18;301(7):737-44
references.pmid: 19224750
references.citation: Bone Marrow Transplant. 2011 Jul;46(7):987-92
references.pmid: 20921942
references.citation: Antimicrob Agents Chemother. 2007 Jul;51(7):2470-82
references.pmid: 17485503
references.citation: Vaccine. 2010 Aug 2;28(34):5558-64
references.pmid: 20600509
references.citation: Can J Neurol Sci. 2004 May;31(2):194-203
references.pmid: 15198443
references.citation: Antiviral Res. 2008 Jan;77(1):56-63
references.pmid: 17888524
references.citation: Clin Infect Dis. 2009 Sep 15;49(6):924-7
references.pmid: 19681709
references.citation: PLoS Negl Trop Dis. 2010 Nov 23;4(11):e892
references.pmid: 21124882
references.citation: J Neurovirol. 2013 Aug;19(4):351-8
references.pmid: 23733308
references.citation: JAMA. 2005 Apr 27;293(16):2003-11
references.pmid: 15855434
references.citation: J Gen Virol. 2006 Sep;87(Pt 9):2467-2476
references.pmid: 16894184
references.citation: J Infect Dis. 2008 Jan 15;197(2):262-5
references.pmid: 18179388
references.citation: Eur J Med Res. 2005 Dec 7;10(12):527-31
references.pmid: 16356868
references.citation: Virology. 2008 Jul 5;376(2):357-70
references.pmid: 18468653
references.citation: J Immunol. 2008 Jul 15;181(2):1563-72
references.pmid: 18606712
references.citation: J Virol. 2008 Sep;82(18):8956-64
references.pmid: 18632856
references.citation: Immunol Rev. 1997 Oct;159:155-61
references.pmid: 9416509
references.citation: J Exp Med. 2006 Jan 23;203(1):35-40
references.pmid: 16418398
references.citation: J Infect Dis. 2006 Nov 1;194(9):1300-8
references.pmid: 17041857
references.citation: Neurology. 2013 Apr 16;80(16):1494-500
references.pmid: 23516318
references.citation: J Exp Med. 2009 Nov 23;206(12):2735-45
references.pmid: 19901080
references.citation: Aliment Pharmacol Ther. 2006 Nov 15;24(10):1423-30
references.pmid: 17081163
references.citation: Vaccine. 2011 Nov 21;29(50):9345-51
references.pmid: 22001884
references.citation: J Virol. 2008 Nov;82(21):10349-58
references.pmid: 18715906
references.citation: Nature. 2012 Nov 29;491(7426):769-73
references.pmid: 23103873
references.citation: Viruses. 2012 Nov 06;4(11):2806-30
references.pmid: 23202506
references.citation: Ann Rheum Dis. 2013 Jan;72(1):37-42
references.pmid: 22523429
references.citation: J Neurochem. 2008 Jun;105(5):1582-95
references.pmid: 18208541
references.citation: Exp Neurol. 2005 Apr;192(2):331-9
references.pmid: 15755550
references.citation: Curr Treat Options Neurol. 2012 Jun;14(3):241-55
references.pmid: 22528294
references.citation: Neurologist. 2012 Mar;18(2):85-7
references.pmid: 22367837
references.citation: Antivir Chem Chemother. 2013 Jan 23;23(3):93-101
references.pmid: 23343513
references.citation: Eur J Immunol. 2007 Jul;37(7):1855-63
references.pmid: 17559175
references.citation: Virus Res. 2012 Jan;163(1):11-8
references.pmid: 21864591
references.citation: Ann Intern Med. 1997 Nov 15;127(10):882-90
references.pmid: 9382366
references.citation: J Infect Dis. 2008 Sep 1;198(5):664-72
references.pmid: 18662130
references.citation: Arch Virol. 2008;153(5):929-37
references.pmid: 18369525
references.citation: Antiviral Res. 2012 Apr;94(1):80-8
references.pmid: 22353544
references.citation: Science. 2007 Sep 14;317(5844):1522-7
references.pmid: 17872438
references.citation: Neurology. 2008 Oct 7;71(15):1160-6
references.pmid: 18838663
references.citation: Clin Infect Dis. 2005 Mar 1;40(5):764-6
references.pmid: 15714427
references.citation: Antiviral Res. 2009 Jun;82(3):95-102
references.pmid: 19428599
references.citation: Clin Infect Dis. 2005 Apr 15;40(8):1173-80
references.pmid: 15791519
references.citation: J Virol. 2011 Jun;85(11):5446-55
references.pmid: 21450826
references.citation: Science. 1991 Nov 8;254(5033):856-60
references.pmid: 1658936
references.citation: Virol J. 2010 May 26;7:106
references.pmid: 20500892
references.citation: Nature. 2012 Dec 6;492(7427):118-22
references.pmid: 23103874